Loading…
← CockpitCompetitor Analysis › 002172.SZ Jiangsu Aoyang Health Industry Co. ltd. Class AOpen in the cockpit ↗

Jiangsu Aoyang Health Industry Co. ltd. Class A002172.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Discretionary›Textiles
Momentum leader 98
Mkt cap
$541M
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$154M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+4.5 pp
WACC 6.1%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥4.93
1D-4.5%
1W-18.5%
1M-11.5%
3M+19.4%
6M+35.1%
YTD+24.2%
1Y+12.6%
ATR %10.8%
52w lowhigh31.1% off high

What Jiangsu Aoyang Health Industry does

Employees: 2,012

Jiangsu Aoyang Health Industry at a glance

Size Jiangsu Aoyang Health Industry (002172.SZ) is a China Consumer Discretionary company (Textiles) with a market value of $541M, the 3502nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.93 on 18 Nov 2026.

Performance Over six months the shares gained 35.1%, against -25.2% for the median peer and -20.0% for the China market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue fell 9.2% over the last twelve months (peer median +7.7%); the operating margin is 3.7% (peer median 6.1%).

Valuation It trades at 2.5× enterprise value to sales against a peer median of 1.7× (6th most expensive of 21).

Capital Return on invested capital runs 4.5 points above its cost of capital (6.1% WACC).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026002172.SZ 136Peer median 77
Six months, rebased to 100: Jiangsu Aoyang Health Industry against the median of its 20 peers (local-currency closes).

Jiangsu Aoyang Health Industry financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.70BCN¥1.81BCN¥2.01BCN¥2.16BCN¥2.01B
Revenue growth—-10%-7%+8%—
Gross profitCN¥233MCN¥223MCN¥243MCN¥256MCN¥239M
EBITDAn/aCN¥148MCN¥158MCN¥164MCN¥166M
Net incomeCN¥38.7MCN¥41.3MCN¥40.6MCN¥49.7M-CN¥15.4M
Free cash flow-CN¥56.5M-CN¥20.0M-CN¥28.2M-CN¥9.29M-CN¥227M
Capital expenditureCN¥16.0MCN¥32.6MCN¥28.6MCN¥63.6MCN¥193M
Total debtCN¥1.02BCN¥1.01BCN¥1.19BCN¥1.45BCN¥1.94B

Quarterly statements and history in the cockpit →

Jiangsu Aoyang Health Industry competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%0%+20%298050600156001312141926784008301077002427310414406051893003840008503008776050550009366015997818002172.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Aoyang Health Industry is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%+40%1×2×3×298050600156001312141926784008301077002427310414406051893003840008503008776050550009366887227818002172.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Aoyang Health Industry is the large dot.

Jiangsu Aoyang Health Industry competitors and peer comparison

How Jiangsu Aoyang Health Industry compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Aoyang Health Industry against its 20 peers (data as of 18 Nov 2026)
Measure002172.SZPeer medianRank in peer set
1-month return-11.5%-8.5%7th lowest of 21
6-month return+35.1%-25.2%highest of 21
Distance from 52-week high-31.1%-40.6%7th highest of 21
Revenue growth (TTM)-9.2%+7.7%4th lowest of 21
Operating margin3.7%6.1%9th lowest of 21
EV / Sales2.5×1.7×6th most expensive of 21
ROIC minus cost of capital+4.5 pp+0.4 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jiangsu Aoyang Health Industry 002172.SZChina$541M+35%-9%4%2.5×n/an/a
Hs Hyosung Advanced 298050.KSSouth Korea$539M-36%+5%6%0.9×2.9%+6.5%
Hunan Huasheng 600156.SSChina$537M-38%-40%-14%6.4×n/an/a
Hangzhou Fuen 001312.SZChina$545M-34%-5%14%1.6×-4.9%-0.8%
Shinkong Textile 1419.TWTaiwan$530M-11%+20%10%2.8×6.6%+17.1%
Texhong International 2678.HKHong Kong$558M-25%+6%8%0.3×-20.6%+2.3%
Sumitomo Seika Chemicals 4008.TJapan$520M+3%+5%9%0.6×-3.3%+7.5%
Zhejiang Chinastars New Materials 301077.SZChina$571M-21%+37%13%3.1×9.9%+4.3%
Zhejiang Unifull Industrial Fiber 002427.SZChina$572M-28%+3%3%1.8×n/an/a
Fujibo 3104.TJapan$580M-36%+14%18%1.6×2.7%+4.5%
Tainan Spinning 1440.TWTaiwan$589M+3%-13%-3%1.7×-0.4%-3.9%
Fuchun Dye and Weave 605189.SSChina$492M-25%+41%6%0.9×-7.1%+17.6%
Beijing Sanlian Hope Shin-Gosen Technical Service 300384.SZChina$492M-25%-36%15%3.3×4.0%-1.3%
Anhui Huamao Textile 000850.SZChina$481M-20%+8%3%1.0×n/an/a
AnHui Jinchun Nonwoven 300877.SZChina$466M-17%+28%3%2.1×15.5%0.0%
Zhejiang Yingfeng Technology 605055.SSChina$459M-45%+11%-5%2.3×20.4%+15.3%
Jiangsu Huaxicun 000936.SZChina$642M-37%+14%-5%1.2×n/an/a
Zhewen Pictures 601599.SSChina$642M+17%+8%2%1.2×11.7%+13.9%
Jiangsu Lianfa Textile 002394.SZChina$453M-22%+1%7%0.5×-9.8%+0.7%
Beijing Tongyizhong New Material Technology 688722.SSChina$440M-30%+7%11%2.9×9.1%+28.0%
Transaction 7818.TJapan$439M+7%+15%20%2.0×-2.7%+13.0%

Questions

Which companies are Jiangsu Aoyang Health Industry's closest peers?
The cockpit's peer set: Hs Hyosung Advanced (298050.KS), Hunan Huasheng (600156.SS), Hangzhou Fuen (001312.SZ), Shinkong Textile (1419.TW), Texhong International (2678.HK), Sumitomo Seika Chemicals (4008.T), Zhejiang Chinastars New Materials (301077.SZ), Zhejiang Unifull Industrial Fiber (002427.SZ).
Is Jiangsu Aoyang Health Industry expensive compared with its peers?
On ev / sales it trades at 2.5× against a peer median of 1.7×, 6th most expensive of 21 in its peer set.
How has Jiangsu Aoyang Health Industry stock performed?
Over six months to 18 Nov 2026 the shares returned +35.1% against -25.2% for the median peer; over one year +12.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.